Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Hadasit and biotech company Anadis are to form a new joint venture company tentatively called Immuron. The mandate of the new company is to develop a new line of therapeutic products for the treatment of several inflammatory diseases, infectious diseases and cancers.
Subscribe to our email newsletter
The products will be based on a combination of intellectual property (IP) from Hadasit and Anadis. Hadasit will contribute user specific methods for the treatment of immune mediated disorders and cancer. Preclinical studies will begin in January to determine the efficacy of the products in animal models.
The preclinical, Phase I and Phase II studies will be conducted at Hadasit at the new Hadassah Clinical Research Center at Hadassah University Hospital in Ein Kerem, Israel. The custom manufacturing of the commercial products will be conducted by Anadis and new intellectual property will be licensed back to Anadis for use in its additional research initiatives.
Dr Oren Fuerst, vice president for business development at Anadis and CEO of Immuron, said: “Hadasit is well known for its enormous pool of IP. It also has a superb reputation as a center of excellence for preclinical and early stage clinical practice. Their clinical deliverables, integrity, and overall commitment to creating therapeutics that will have a positive global impact make partnership with Hadasit a natural choice. I anticipate that over the next five years the competitive landscape of biotherapy will be completely altered, with our new venture playing a central role.”